Panadol, the flagship brand of SmithKline Beecham (GlaxoSmithKline) and the nation’s most sought-after pain reliever, was recently ranked Sri Lanka’s second “Most Loved Brand” according to Brand Finance’s 2018 ranking, a press release stated.
This follows Panadol being ranked seventh place in the ‘Most Loved Brand’ category for Sri Lanka in 2017, as well as consistently coming in within the top 10 over several years, the release added.
Panadol, a heritage pharmaceutical brand, has brought the gentle touch of caring and relief to millions of Sri Lankans. Over the past 50 years, Panadol has become more than the nation’s most sought-after pain reliever, evolving to become a time-honored friend always helping to bring comfort and soothe life’s physical aches and pains during the moments that matter.
Commenting on the achievement, Consumer Healthcare GSK, Sri Lanka Managing Director Sunil Mehra said, “Panadol has been a trusted friend and pain reliever for Sri Lankans for over five decades, and has become an essential part of their everyday lives. The foremost reason that has made this accomplishment possible is a relentless focus on the pain relief proposition throughout the brand’s 50-year journey and we will continue to communicate it effectively to our consumers, in newer and more innovative ways.
We thank Brand Finance and the people of Sri Lanka for placing their trust in us.”
Panadol is the flagship brand of GlaxoSmithKline, a multinational healthcare company that also manufacture and distribute household products such Horlicks, Sensodyne, Viva, Eno and Iodex.
During its five-decade long history in Sri Lanka, Panadol has been the driving force of several initiatives to promote safe and responsible use of medicine. Panadol is the first and only brand to introduce a child resistant cap to its liquid Paracetamol product range, ‘Panadol for Children’.
In 2012, a state-of-the-art Panadol manufacturing facility in Ratmalana was established with an investment of Rs 217 million, making it one of the largest Foreign Direct Investments in the pharmaceuticals sector in Sri Lanka, the release concluded.